Another pill to fight obesity won US approval, pitting Lilly’s Foundayo against Novo’s Wegovy pill in the race to dominate a market worth billions. Patients and consumers may also be winners, as prices fall and selection expands. https://t.co/1upjiYnPww ...

The FDA approved Eli Lilly’s new weight-loss pill, setting up a fight with rival Novo Nordisk over the next front in the booming market https://t.co/1j0gqhoXlH ...

Eli Lilly & Co.’s weight-loss pill won US approval, ratcheting up pressure on Novo Nordisk A/S, which launched an obesity pill earlier this year. https://t.co/FDknJHod96 ...

Core Insights - Novo Nordisk's stock rose by as much as 4% following a recommendation from England's drug price regulator to use its drug Wegovy for preventing heart attacks and strokes [1] - The recommendation from the National Institute for Health and Care Excellence (NICE) will significantly increase access to Wegovy through the National Health Service (NHS) in England [2] - NICE has recommended semaglutide, the active ingredient in Wegovy, for adults with a BMI of at least 27 who have a history of heart attack, stroke, or serious circulation issues [3] Group 1 - Novo Nordisk's shares were observed to be up 2% in morning trading, reflecting a positive market response [3] - The broader market, represented by the pan-European blue-chip index Stoxx 600, also saw an increase of 2.1% [3]

Healthcare - The UK's NICE has recommended Novo Nordisk's Wegovy (2.4mg) for reducing the risk of major cardiovascular events in adults with cardiovascular disease and obesity, marking a significant milestone for GLP-1 medications in cardiovascular prevention [2][9] - The final guidance for the treatment is expected by the end of April 2026, with plans for integration into existing NHS cardiovascular care pathways, potentially broadening the market for weight-loss drugs [3][9] Trade - The U.S. government is launching a digital refund portal for $166 billion in duties collected under the Trump administration's tariffs, following a Supreme Court ruling that deemed these tariffs unlawful [4][9] - The Treasury is adopting a "Digital Only" payment model via the ACE portal to manage the volume of claims, emphasizing the need for businesses to ensure their ACH setup is active [5] Energy & Tech - Microsoft and Engine No. 1 are in discussions for a $7 billion natural gas-fired power project in Texas, aimed at providing dedicated electricity for a large-scale data center campus [6][9] - Chevron has clarified that no commercial terms have been finalized for its participation in the project, which reflects a trend of tech companies securing energy resources for AI workloads [7] Asia-Pacific - Australia's S&P/ASX 200 index rose 1.6% to 8,618.20, supported by government signals of assistance for the private sector, including potential payment deferrals and loan restructuring [8][9] - The Australian government signed a Memorandum of Understanding with Anthropic to collaborate on AI safety and economic data tracking, marking the first arrangement under the National AI Plan [10] Commodities & Crypto - Gold prices have maintained a three-day gain amid shifting geopolitical tensions, with President Trump's comments suggesting a potential end to hostilities with Iran, leading to a drop in crude oil prices [11] - CoinShares is set to begin trading on the Nasdaq following a SPAC merger, valuing the crypto manager at approximately $1.2 billion and enhancing its presence in the U.S. market [12]

Core Viewpoint - The UK's drug cost-effectiveness watchdog, NICE, has recommended Novo Nordisk's Wegovy for reducing the risk of serious heart problems or strokes in obese or overweight adults, marking it as the first GLP-1 drug endorsed for this purpose [1][2]. Group 1: Drug Approval and Recommendations - Wegovy, at a 2.4-milligram dose, will be available through the National Health Service (NHS) following NICE's recommendation [2]. - The drug will be integrated into existing cardiovascular treatment pathways, allowing healthcare providers to consider it alongside standard therapies for secondary prevention of heart issues in overweight or obese adults [2]. Group 2: Clinical Evidence - NICE's recommendation was based on a study involving over 17,600 participants, demonstrating that Wegovy reduced the risk of major cardiovascular events by 20% compared to a placebo [3]. - In 2024, Wegovy received UK regulatory approval to reduce the risk of major cardiovascular events in obese or overweight adults with preexisting heart disease, although initial access was limited to patients paying out-of-pocket [3]. Group 3: Market Context - Approximately one in four adults in the UK is estimated to be living with obesity, highlighting a significant market for weight-loss and cardiovascular drugs [4]. - Eli Lilly, a competitor, has raised the UK list price for its weight-loss drug Mounjaro by up to 170% last year, indicating competitive pricing pressures in the market [5].

Core Insights - Eli Lilly and Novo Nordisk are leveraging artificial intelligence (AI) to transform drug development processes, significantly impacting the speed at which new medicines are delivered to patients [1][4]. Eli Lilly - Eli Lilly has entered a $2.75 billion partnership with Insilico Medicine, gaining exclusive rights to develop drugs using Insilico's Pharma.ai platform, which has already produced 28 drug candidates, with nearly half in clinical testing [3][7]. - The company has implemented AI technologies in its manufacturing processes, including digital twin technology and computer vision, to enhance production efficiency and quality control [5]. - Eli Lilly's revenue from GLP-1 drugs has seen substantial growth, with Mounjaro sales doubling to $23 billion and Zepbound revenue increasing from $4.9 billion to $13.5 billion, contributing to over half of the company's total revenue of $65 billion [6]. Novo Nordisk - Novo Nordisk has generated nearly $100 billion in cumulative sales from its drugs Ozempic and Wegovy, focusing on reducing clinical trial durations through AI agents trained on internal and competitor data [12]. - The AI agents are actively used in clinical trials to identify protocol gaps and manage data, which has reduced reliance on external contractors for analytical tasks [13]. - Novo Nordisk has partnered with Nvidia to utilize the Gefion sovereign AI supercomputer for large-scale drug discovery, emphasizing the financial impact of reducing time-to-market for new drugs [14]. - The company has been selective in rolling out AI tools, learning from experiences where costs outweighed benefits, indicating a strategic approach to AI implementation [15]. Industry Implications - The integration of AI across various stages of drug development, from discovery to manufacturing and clinical execution, is creating a competitive advantage that traditional productivity enhancements cannot achieve [16].

Core Viewpoint - Novo Nordisk has announced a new multi-month drug subscription plan aimed at providing predictable pricing for self-pay patients, amidst a significant decline in its stock price, which is down over 75% from its all-time high in June 2024 [1][3][12]. Summary by Sections Subscription Plan Details - The subscription plan targets self-pay patients, offering them a predictable monthly price to address the fluctuating costs of obesity treatments [3][4]. - Patients can choose between three, six, or twelve-month subscription plans for either the WGOi injection or the WGOI pill, with longer subscriptions resulting in lower monthly prices [7][9]. - The subscription can save patients up to $600 annually for the pill and up to $1,200 for the injection [8]. Pricing Structure - The pricing for the subscription plans is as follows: - Three-month plan: $329 per month, saving $240 annually - Six-month plan: $299 per month - Twelve-month plan: $249 per month [9][10]. - The subscription offers a flat fee regardless of dosage, contrasting with other deals that may only apply to the first month or two [9]. Market Reaction and Valuation - Following the announcement of the subscription plan, Novo Nordisk's stock rose by 2.5% [11]. - The stock is currently trading at a price-to-earnings (PE) ratio under 10, indicating it is at a cheap valuation level [12]. - The stock has been described as oversold, with technical indicators suggesting it may have found support around the $35 level [12][15].

The company is trying to win customers by offering a "lower, predictable monthly price†for its obesity drugs. ...

Group 1 - Novo Nordisk announced a first-of-its-kind subscription program for its weight loss therapy Wegovy (semaglutide) [4] - The subscription program is available on telehealth platforms, including LifeMD and Hims & Hers [4] - Cash-paying patients can choose from 3-, 6-, or 12-month subscription options [4]